Kelly Jaziri
Psychiatry · Norwich, CTNPI 1891130597
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,362 of the $20,569 with a category attached, or 69.8%. 39 manufacturers reported payments, led by AbbVie at 40.5% of the total. Reporting peaked in 2020 at $5,137 and has fallen 61.4% since, to $1,984 in 2025. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 682 payments — averaging $30.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Vanda Pharmaceuticals Inc.$2K
- Lundbeck LLC$911
- Bausch Health US, LLC$738
- Johnson & Johnson$606
- plus $6K from 33 others
What the payments were for
- Speaking & faculty fees$6,05029%
- Travel & lodging$580%
- Food & beverage$14,36270%
- Education$990%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,569 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 17 | $18,731 |
| Aripiprazole | 14 | $1,969 |
| Methylphenidate Er (La)Methylphenidate Hcl | 12 | $1,740 |
| Bupropion XlBupropion Hcl | 34 | $1,079 |
| Lorazepam | 72 | $432 |
| Trazodone Hcl | 21 | $405 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $404 |
| Duloxetine Hcl | 21 | $393 |
| Fluoxetine Hcl | 37 | $356 |
| Quetiapine Fumarate | 23 | $350 |
| Alprazolam | 13 | $208 |
| Zolpidem Tartrate | 28 | $158 |
| Escitalopram Oxalate | 11 | $100 |
| Clonazepam | 47 | $88 |
| Lamotrigine | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $523 | $18,73117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Norwich
- Mahmoud OkashaNorwich$20K
- Walid JaziriNorwich$17K
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.